Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $14.6 million.

  • Ocular Therapeutix's Other Operating Expenses rose 2055.51% to $14.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $60.5 million, marking a year-over-year increase of 2812.61%. This contributed to the annual value of $60.5 million for FY2025, which is 2812.61% up from last year.
  • Per Ocular Therapeutix's latest filing, its Other Operating Expenses stood at $14.6 million for Q4 2025, which was up 2055.51% from $14.9 million recorded in Q3 2025.
  • In the past 5 years, Ocular Therapeutix's Other Operating Expenses ranged from a high of $15.7 million in Q2 2025 and a low of $9.0 million during Q1 2021
  • Its 5-year average for Other Operating Expenses is $11.9 million, with a median of $11.5 million in 2024.
  • As far as peak fluctuations go, Ocular Therapeutix's Other Operating Expenses soared by 5618.36% in 2021, and later crashed by 790.89% in 2023.
  • Ocular Therapeutix's Other Operating Expenses (Quarter) stood at $10.2 million in 2021, then rose by 12.69% to $11.5 million in 2022, then decreased by 7.91% to $10.6 million in 2023, then increased by 13.54% to $12.1 million in 2024, then rose by 20.56% to $14.6 million in 2025.
  • Its last three reported values are $14.6 million in Q4 2025, $14.9 million for Q3 2025, and $15.7 million during Q2 2025.